Literature DB >> 10768303

Clinical pharmacology of topiramate: a review.

W R Garnett1.   

Abstract

Clinical success with an antiepileptic drug (AED) depends primarily on its efficacy and tolerability. Clinicians also need to have a basic understanding of an AED's pharmacokinetic characteristics, particularly those affecting the potential for drug interactions such as hepatic enzyme inhibition or induction and protein-binding displacement. Successful treatment may be complicated by pharmacokinetic characteristics such as a short half-life, nonlinear kinetics, and active metabolites. Pharmacokinetic characteristics that make a drug easy to use may affect patient adherence. In general, newer AEDs such as topiramate (TPM) are simpler to use than traditional AEDs because they have more favorable pharmacokinetic characteristics and fewer drug interactions.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10768303     DOI: 10.1111/j.1528-1157.2000.tb02174.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  33 in total

Review 1.  Prophylactic migraine therapy: emerging treatment options.

Authors:  Marcelo E Bigal; Abouch V Krymchantowski; Alan M Rapoport
Journal:  Curr Pain Headache Rep       Date:  2004-06

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Topiramate Confers Neuroprotection Against Methylphenidate-Induced Neurodegeneration in Dentate Gyrus and CA1 Regions of Hippocampus via CREB/BDNF Pathway in Rats.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Mohammad Abdollahi; Mansour Heidari; Zahra Madjd
Journal:  Neurotox Res       Date:  2017-01-11       Impact factor: 3.911

Review 4.  Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

Authors:  Bankole A Johnson; Nassima Ait-Daoud
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

5.  Pharmacokinetic-pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers.

Authors:  Ghada F Ahmed; Susan E Marino; Richard C Brundage; Serguei V S Pakhomov; Ilo E Leppik; James C Cloyd; Annie Clark; Angela K Birnbaum
Journal:  Br J Clin Pharmacol       Date:  2015-05       Impact factor: 4.335

Review 6.  Topiramate in Alcohol Use Disorders: Review and Update.

Authors:  Riccardo Guglielmo; Giovanni Martinotti; Marianna Quatrale; Lucia Ioime; Irket Kadilli; Marco Di Nicola; Luigi Janiri
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

7.  Neuroprotective effects of various doses of topiramate against methylphenidate-induced oxidative stress and inflammation in isolated rat amygdala: the possible role of CREB/BDNF signaling pathway.

Authors:  Majid Motaghinejad; Manijeh Motevalian; Reza Falak; Mansour Heidari; Mahshid Sharzad; Elham Kalantari
Journal:  J Neural Transm (Vienna)       Date:  2016-09-24       Impact factor: 3.575

Review 8.  Pharmacokinetic interactions of topiramate.

Authors:  Meir Bialer; Dennis R Doose; Bindu Murthy; Christopher Curtin; Shean-Sheng Wang; Roy E Twyman; Stefan Schwabe
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Tolerability and safety of topiramate in Chinese patients with epilepsy : an open-label, long-term, prospective study.

Authors:  Yang Lu; Xuefeng Wang; Qihua Li; Jingmei Li; Yong Yan
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

10.  Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions.

Authors:  William R Garnett; Erik K St Louis; Thomas R Henry; Thomas Bramley
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.